Sector News

Still seeking cost cuts, Sanofi plans to slim down in Japan through voluntary retirements

October 1, 2019
Life sciences

Still under pressure in diabetes and struggling to bring enough lucrative new meds to market, Sanofi has been paring away jobs on both sides of the Atlantic. Now, it’s Japan’s turn.

The drugmaker plans to eliminate positions in Japan through voluntary early retirements, the company confirmed Monday.

Jobs in sales, regulatory affairs, operations, IT and human resources are on the block, according to Reuters, which cites an unnamed person familiar with the planned cuts.

A Sanofi representative told FiercePharma that “Sanofi Japan plans to implement a voluntary retirement program in order to adapt to the external environment changes and to transform our business models to continue our growth.”

At the end of 2018, Sanofi employed 5,864 workers in its “rest of the world” category, which includes Japan; the drugmaker doesn’t break out its Japanese employment numbers specifically. Worldwide, the company employed 104,266 workers at the end of the year, down slightly from 106,566 at the end of 2017 and 106,859 at the end of 2016.

The reported cuts come after Sanofi in June chopped 466 jobs in its R&D organization in France and Germany as part of a pivot away from cardiovascular diseases and toward cancer drugs and gene therapy. In April, the company said it planned to lay off an undisclosed number of U.S. sales staffers.

For years, Sanofi has implemented various layoffs in the U.S. and Europe as it’s dealt with pricing pressure in its diabetes and cardiovascular units, generic competition to older meds and a thin pipeline of new blockbuster prospects. The report of the latest cuts comes as new CEO Paul Hudson settles into the job; he took up the reins at the beginning of September.

Also in September, the company discussed exiting Bangladesh, creating uncertainty for more than 1,000 workers there, according to reports. A spokesperson said Sanofi will prioritize its employees’ interests and drug access in the country as it reviews various scenarios for its operations.

By Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend